Aytu BioPharma (AYTU) SEC Filings: History & Chart

Aytu BioPharma, Inc.(AYTU)

Drug Manufacturers - Specialty & Generic · Denver, CO

$2.06+0.02 (+1.17%)

Delayed quote: Oct 6, 2026, 2:32 PM EDT

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Denver, CO

76 employees

aytubio.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Joshua R. Disbrow

View full financials

Form	Filing Date	Accepted	Document
10-K	Sep 22, 2026	Sep 22, 2026	View filing
8-K	Sep 22, 2026	Sep 22, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
10-Q	May 13, 2026	May 13, 2026	View filing
8-K	May 13, 2026	May 13, 2026	View filing
8-K	Apr 2, 2026	Apr 2, 2026	View filing
SC 13G/A	Feb 17, 2026	Feb 17, 2026	View filing
SC 13G/A	Feb 13, 2026	Feb 13, 2026	View filing
10-Q	Feb 3, 2026	Feb 3, 2026	View filing
8-K	Feb 3, 2026	Feb 3, 2026	View filing
8-K	Jan 20, 2026	Jan 20, 2026	View filing
8-K	Dec 10, 2025	Dec 10, 2025	View filing
SC 13G/A	Nov 14, 2025	Nov 14, 2025	View filing
10-Q	Nov 13, 2025	Nov 13, 2025	View filing
8-K	Nov 13, 2025	Nov 13, 2025	View filing
SC 13G/A	Nov 12, 2025	Nov 12, 2025	View filing
ARS	Oct 24, 2025	Oct 24, 2025	View filing
DEFA14A	Oct 24, 2025	Oct 24, 2025	View filing
DEF 14A	Oct 24, 2025	Oct 24, 2025	View filing
5	Oct 20, 2025	Oct 20, 2025	View filing
4	Oct 7, 2025	Oct 7, 2025	View filing

SEC Filings

Recent Filings